Can pancreatic Cancer's inflammatory footprint be stopped?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * For all participants: * Age ≥18 years. * Ability and willingness to autonomously provide written informed consent. * For the PDAC cohort: * Clinical diagnosis of non-metastatic pancreatic ductal adenocarcinoma (PDAC). * Treatment-naïve status at the time of blood collection, with no prior chemotherapy, radiotherapy, or immunotherapy for PDAC. * Newly diagnosed non-metastatic pancreatic cancer eligible for multimodal treatment. * Candidate for standard clinical management at IRCCS Ospedale San Raffaele. * For the age-matched control cohort: * Patient followed at the Pancreatic Cystic Lesion outpatient clinic of IRCCS Ospedale San Raffaele. * Diagnosis of intraductal papillary mucinous neoplasm (IPMN) under surveillance, with no evidence of pancreatic malignancy at the time of enrollment. * Age within ±5 years of the corresponding PDAC cohort to allow age-matched comparator analyses. * Exclusion Criteria * For all participants: * Inability to autonomously provide informed consent. * For the PDAC cohort: * Failure to meet the inclusion criteria for the PDAC cohort. * Presence of severe comorbidities that, in the investigator's opinion, may interfere with study participation or interpretation of study results. * Previous systemic anti-cancer treatment for PDAC. * Use of anti-inflammatory drugs, including NSAIDs or immunomodulators. * Events or conditions affecting inflammatory parameters, including acute inflammatory or infectious events such as cholangitis, jaundice, or recent invasive procedures. * Hematologic diseases. * Clinically significant hematological abnormalities that may interfere with immune profiling analyses, as assessed by the investigator. * For the age-matched control cohort: * Any acute or chronic inflammatory condition or ongoing infection. * Any history of cancer or immunological disorders.